Advertisement

Antibody–Cytokine Fusion Proteins with Members of the TNF-Family

  • Dafne MüllerEmail author
  • Jeannette Gerspach

Abstract

The generation of antibody fusion proteins for target-directed delivery of cytokines constitutes a promising immunotherapeutic approach. The fusion of recombinant antibodies to members of the TNF-family that differ clearly in their soluble and membrane-bound forms for their receptor activating capacities is therefore of special interest because binding of the antibody moiety implies the presentation of the cytokine in a membrane-associated form, affecting directly the cytokine activity. Here we describe the generation and characterization of two of these antibody–cytokine fusion proteins composed of a tumor specific scFv and the extracellular domain of CD95L (scFv-CD95L) or CD137L (scFv-CD137L), respectively. Protocols are indicated for cloning, expression in mammalian cells, purification, and functional characterization in terms of costimulatory and cytotoxicity properties.

Keywords

Fusion Protein Cell Culture Supernatant Eukaryotic Expression Vector Crystal Violet Solution Flag Peptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Gerspach J, Wajant H, Pfizenmaier K (2009) Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results and Problems in Cell Differenciation, Vol. 49. Springer-Verlag, Berlin-Heidelberg, pp 241–273Google Scholar
  2. Kaspar M, Trachsel E, Neri D (2007) The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 67(10):4940–4948PubMedCrossRefGoogle Scholar
  3. Müller D, Frey K, Kontermann RE (2008) A novel antibody-4–1BBL fusion protein for targeted costimulation in cancer immunotherapy. J Immunother 8:714–722CrossRefGoogle Scholar
  4. Ortiz-Sánchez E, Helguera G, Daniels TR, Penichet ML (2008) Antibody–cytokine fusion proteins: applications in cancer therapy. Expert Opin Biol Ther 5:609–632CrossRefGoogle Scholar
  5. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory Press, New YorkGoogle Scholar
  6. Samel D, Muller D, Gerspach J, Assohou-Luty C, Sass G, Tiegs G, Pfizenmaier K, Wajant H (2003) Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation. J Biol Chem 78(34):32077–32082CrossRefGoogle Scholar
  7. Watermann I, Gerspach J, Lehne M, Seufert J, Schneider B, Pfizenmaier K, Wajant H (2007) Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death Differ 14:765–774PubMedCrossRefGoogle Scholar
  8. Wörn A, Plückthun A (2001) Stability engineering of antibody single-chain Fv fragments. J Mol Biol 305:989–1010PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Institute of Cell Biology and ImmunologyUniversity of StuttgartStuttgartGermany

Personalised recommendations